Jefferies & Co Downgrades MDS Inc. (MDZ) to Hold; Valuation Call
More News related to MDZ
- MDS Nordion's TheraSphere(R) for Unresectable Liver Cancer (HCC) Now Covered by Two Large U.S. Insurers
- Notable Mergers and Acquisitions of the Day 02/01: CEPH, SUN/BAK, MDZ/DHR
- MDS (MDZ) Appoints William Anderson to Chairman of Board
- MDS (MDZ) Completes $650M Divestiture of Analytical Tech Business to Danaher Corp. (DHR)
- MDS Inc. Announces Appointment of William D. Anderson as Chair of Board of Directors
More News related to Downgrades
- S&P Lowers Pinnacle Entertainment (PNK) Outlook from Stable to Negative
- Mindspeed (MSPD) Moving Lower as Brigantine Downgrades to Hold
- Davenport Downgrades Electronic Arts (ERTS) to Sell; Lowers Q4, 2010-11 Estimates
- Stifel Nicolaus Downgrades Parkway Properties (PKY) to Sell
- Craig-Hallum Downgrades Terremark (TMRK) to Accumulate
Jefferies & Co downgrades MDS Inc. (NYSE: MDZ) from Buy to Hold. Price target $9
To see more analyst ratings on MDZ Click Here.
MDS, Inc., a life sciences company, provides products and services for the development of drugs, and the diagnosis and treatment of diseases.
Related Categories
DowngradesStocks Mentioned
+0.11Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
